From April 11 to 15, 2025, Olha Yungin, Associate Professor at the Department of Biotechnology, Leather and Fur (BLF), participated in the ESCMID Global 2025 Congress organized by the European Society of Clinical Microbiology and Infectious Diseases in Vienna, Austria. She presented research findings on the effectiveness of innovative antibiotic therapy against pandrug-resistant infectious agents. The study was conducted by a team of scientists within the framework of the Horizon SURE-AMR project (https://sure-amr.eu/), in collaboration with the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine.
ESCMID Global is a major international event that brings together leading experts in infectious diseases, infection control, and clinical microbiology from around the world. Organized annually by the European Society of Clinical Microbiology and Infectious Diseases, the Сongress aims to unite professionals, promote the exchange of ideas and knowledge among researchers, clinicians, industry representatives, and public health experts, and to share the latest scientific advancements and innovations in clinical microbiology. It also serves as a vital platform for networking and international collaboration. This year, particular attention was given to the issue of antibiotic resistance in Ukraine, including the challenges of combating it under wartime conditions. Ukrainian researchers made a significant contribution to the Congress by presenting 24 reports.
Two of the reports were co-authored by Olha Yungin and addressed pressing contemporary issues. The first, “Azithromycin-Meropenem Combination Therapy is Effective for Treating PDR Infections Caused by Gram-Negative Bacteria in Immunocompromised Patients: A Case Series of Urinary Tract Infections in Kidney Transplant Recipients,” examined the clinical outcomes of innovative treatment strategies in vulnerable populations. The second report, “Antibiotic Resistance and Genetic Characteristics of Clinical Pathogens from a Kyiv Clinic Serving Patients from Across Ukraine”, focused on the molecular profiling and resistance patterns of pathogens in a national clinical setting.
We work, we research – we win! Together to our Victory!
08.05.2025
